For women with an intact uterus as an adjunct to postmenopausal estrogen replacement therapy to significantly reduce the risk of endometrial hyperplasia and cancer.
Progynorm Gesta Composition and form of release
Main active ingredient: progesterone.
The excipients included in the preparation: peanut butter, lecithin, gelatin, glycerin, titanium dioxide.
Produced in capsule form, 200 mg each.
This pharmaceutical agent Progynorm Gesta belongs to hormonal drugs-gestagens used in gynecology.
The main active ingredient is progesterone. This is a hormone of natural origin, produced in women with the help of the so-called “yellow body” – one of the most important progesterone receptors in the female body.
A particularly large amount of this hormone is produced in women in the placenta during pregnancy, during the period that begins at the end of the first trimester.
Progesterone has several physiological effects that affect some of the organs that are the main targets in this case. These include: gestagens, antiestrogens, antiandrogens, and antialdosterones.
Has the ability to bind selectively to progesterone receptors. It is an agonist of many membrane receptors. Able to stimulate some liver enzymes.
When treated with microdoses of natural progesterone, it is highly effective, with no masculine effects and no effect on the lipid profile after estrogens are administered.
This drug Progynorm Gesta is used in the treatment of genital diseases in women.
In particular, it is used in the treatment of women with an intact uterus in addition to estrogen replacement therapy in the postmenopausal period, to significantly reduce the risk of preterm birth, endometrial hyperplasia and cancer.
The drug in question is contraindicated for use in cases where the patient has severe hypersensitivity (allergy) to the main or to one of the auxiliary components.
Use is contraindicated in:
- severe liver dysfunction;
- neoplasia of the breast or genitals;
- vaginal bleeding, suspected hormone-dependent neoplasms, incl. malignant;
- unsuccessful or incomplete abortion;
- thrombophlebitis, thromboembolic disorders, vascular diseases of the eyes;
- cerebral hemorrhage, migraines;
Treatment in recommended doses has no contraceptive effect.
Application during pregnancy and lactation
This drug can be used in the treatment of pregnant women only as directed by a doctor. The use of progesterone after 36 weeks of gestation is not recommended.
If it is necessary to administer the drug during breastfeeding, then during treatment, lactation should be suspended.
Method of administration and dosage
The duration of treatment depends on the disease. Dosage, treatment regimens, duration of treatment are determined individually by the attending physician, depending on the indicators of a particular patient. 200 mg of the drug – once a day, injected deep into the vagina, before going to bed.
Overdose can cause symptoms:
- nausea, vomiting;
- dizziness, tiredness;
- acne, hirsutism.
Symptomatic treatment is recommended.
The drug is well tolerated.
Possible side effects:
- change in menstruation, amenorrhea, intermittent vaginal bleeding, mastodynia;
- headache, drowsiness, dizziness, depression;
- nausea, vomiting, diarrhea, death;
- itching, acne, chloasma, urticaria;
- thromboembolism, alopecia, hyperthermia;
- candidiasis, vaginal irritation, vaginal discharge.
Storage conditions and periods
Expiration date – up to 3 years from the production date indicated on the package.
Storage temperature Progynorm Gesta – no more than 25 ° C.